Passenger co-deletion confounds glutaminolysis signatures anchored on PTEN loss: a cautionary case for location-aware signature design
PTEN-deficient tumors are widely assumed to be glutamine-dependent, a view that has helped motivate the clinical development of glutaminase inhibitors. Whether glutaminolytic transcription scales with PTEN copy-number loss in human tumors, and by what mechanism, has not been established. We classified TCGA PanCancer Atlas tumors by GISTIC copy number as PTEN intact, hemizygous, or homozygous…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
